Navigation Links
AMRI Announces 3-Year Extension of Insourcing Contract
Date:1/12/2016

ALBANY, N.Y., Jan. 12, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) is pleased to announce the extension of a key insourcing relationship with a major pharmaceutical company designed to accelerate their chemistry and drug discovery efforts. The original insourcing collaboration, which commenced in 2011, is being extended significantly beyond its original termination date of December 2018 to December 31, 2021.

"Insourcing relationships provide the benefit of accelerating drug discovery, drug product and manufacturing efforts by maximizing the real-time exchange of scientific information and enabling scientists to rapidly adapt to changing project needs," said Michael P. Trova, Senior Vice President, Chemistry, AMRI. "We find these relationships are mutually beneficial and will be an important key to the long-term development and success of AMRI's DDS business unit. We look forward to finding new ways to deepen and extend these unique arrangements."

"The insourcing model is a fusion of the best elements of external outsourcing and in-house R&D activities," said Christopher Conway, Senior Vice President of Discovery and Development Services, AMRI. "With expertise in managing high performing groups of scientists, AMRI developed this business model in order to embed its own scientists into the customer's facility, allowing the customer to cost-effectively leverage their underutilized laboratory space and resources."

About Albany Molecular Research Inc.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent, controlled substances, biologics, peptides, steroids, hormones, cytotoxic compounds and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations.

Forward-Looking Statements 
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties.  These statements include, but are not limited to, statements regarding the term or extension of customer contracts, the benefits to be derived by the company from its insourcing or other customer relationships, and the potential impact on the long-term results of the company's business unit(s).  Readers should not place undue reliance on our forward-looking statements.  The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company the company may not be able to predict and may not be within the company's control.  Factors that could cause such differences include, but are not limited to, the ability of the company to hire and retain qualified scientists to provide insourcing services, the risk of a decrease in customers' demand for the company's services, including but not limited to early termination of customer contracts, as well as those risks discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2014 as filed with the Securities and Exchange Commission on March 16, 2015, and the company's other SEC filings.

For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

 


'/>"/>
SOURCE AMRI
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. HeartWare International Provides Corporate Updates And Announces Preliminary Revenue For Fourth Quarter 2015
2. Mauna Kea Technologies Announces the Appointment of Joseph DeVivo as a Non-Executive Director
3. KaloBios Pharmaceuticals, Inc. Announces Board Changes and New Appointments
4. Bio2 Technologies, Inc. Announces Receipt of FDA 510(k) Clearance for a Fusion Implant System for Extremities Surgery
5. NuMedii, Inc. Announces New Indications Discovery Collaboration With Astellas
6. Medicure Announces Preliminary Revenue For Fiscal 2015
7. Worlds Largest Materials Science Catalog Announces Launch Of New Website
8. Agena Bioscience Announces the Expansion of its Headquarters in San Diego, California, to Better Serve its Growing Customer Base
9. Nevro Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2015 Revenue
10. Sorrento Announces Positive Data from Phase 3 studies of Biosimilar Antibodies, STI-001 and STI-002
11. Exact Sciences Announces Preliminary Fourth Quarter and Full Year 2015 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2018)... ... September 06, 2018 , ... This year, the California ... Award for his presentation of: IDEAL IMPLANT® - Seven-Year Clinical Trial Results at the ... paper again at the upcoming ASPS (American Society of Plastic Surgeons) meeting in Chicago ...
(Date:9/7/2018)... ABILENE, Texas (PRWEB) , ... September 07, 2018 , ... Yisrayl Hawkins, Pastor and Overseer ... that reveals the True Name of the Creator and says the proof is undeniable. , ... be used in place of the Creator’s Name. Yisrayl shows there is great meaning in ...
(Date:9/1/2018)... ... August 31, 2018 , ... Precision Orthopedics & Sports Medicine announced ... Irving and Southlake. Fellowship trained in Spine Surgery, Dr. Gengler will practice alongside ... Milani, Dr. Jaytinder Sandhu, and Dr. Tariq Hendawi beginning September 4, 2018. ...
Breaking Medicine Technology:
(Date:9/24/2018)... ... September 24, 2018 , ... Smile Brands Inc . was ... the Year and People-Focused CEO of the Year in the third annual Stevie Awards ... employers and the human resources professionals, teams, achievements and HR-related products and suppliers who ...
(Date:9/24/2018)... ... September 24, 2018 , ... Oak Street Health , a network ... has added the Little Village center to its Chicago operations. With the addition of ... solidifies the company’s vision of providing care for adults on Medicare in areas where ...
(Date:9/24/2018)... WORCESTER, Mass. (PRWEB) , ... September 24, 2018 ... ... Americans virtually always have with them may become an early warning system for ... by a team of computer scientists at Worcester Polytechnic Institute (WPI). The researchers ...
(Date:9/22/2018)... ... 2018 , ... Liz Dudek, Director of Health Care Affairs for global law ... of the Florida Assisted Living Association (FALA) at 10:00 a.m. at Tessera of Brandon ... an overview of the success of the first five years of Florida’s Statewide Medicaid ...
(Date:9/22/2018)... ... September 22, 2018 , ... Nonprofit and not-for-profit organizations ... different categories listed in section 501(c) of the Internal Revenue Code under which ... as a 501(c)(3)), private foundations, political organizations, and others such as chambers of ...
Breaking Medicine News(10 mins):